DRRX Stock Summary and Trading Ideas (Durect | NASDAQ:DRRX)

Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from the Europe .

Durect trades on the NASDAQ stock market under the symbol DRRX.

As of April 16, 2024, DRRX stock price declined to $0.77 with 29,080 million shares trading.

DRRX has a beta of 1.03, meaning it tends to be more sensitive to market movements. DRRX has a correlation of 0.00 to the broad based SPY ETF.

DRRX has a market cap of $22.97 million. This is considered a Sub-Micro Cap stock.

Last quarter Durect reported $3 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $189,000 and exceeded earnings estimates by $.23.

In the last 3 years, DRRX stock traded as high as $19.30 and as low as $.47.

The top ETF exchange traded funds that DRRX belongs to (by Net Assets): VTI, VXF, IWC.

DRRX has underperformed the market in the last year with a price return of -83.0% while the SPY ETF gained +23.6%. However, in the short term, DRRX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +17.0% vs +5.9% return in SPY. But in the last 2 weeks, DRRX shares have been beat by the market, returning -30.6% compared to an SPY return of -3.6%.

DRRX support price is $.73 and resistance is $.86 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DRRX stock will trade within this expected range on the day.